Skip to main content
Erschienen in: Reactions Weekly 1/2012

01.08.2012 | Case report

Bevacizumab/ranibizumab

Ocular hypertension following intravitreal administration: 23 case reports

Erschienen in: Reactions Weekly | Ausgabe 1/2012

Einloggen, um Zugang zu erhalten

Excerpt

An event is serious (FDA MedWatch definition) when the patient outcome is:
  • death
  • life-threatening
  • hospitalisation
  • disability
  • congenital anomaly
  • requires intervention to prevent permanent impairment or damage
Literatur
1.
Zurück zum Zitat Tseng JJ, Vance SK, Della Torre KE, Mendonca LS, Cooney MJ, Klancnik JM, Sorenson JA, Freund KB.Sustained increased intraocular pressure related to intravitreal antivascular endothelial growth factor therapy for neovascular age-related macular degeneration. Journal of Glaucoma 21: 241-7, No. 4, Apr-May 2012. Available from: URL: http://dx.doi.org/10.1097/IJG.0b013e31820d7d19 - USA Tseng JJ, Vance SK, Della Torre KE, Mendonca LS, Cooney MJ, Klancnik JM, Sorenson JA, Freund KB.Sustained increased intraocular pressure related to intravitreal antivascular endothelial growth factor therapy for neovascular age-related macular degeneration. Journal of Glaucoma 21: 241-7, No. 4, Apr-May 2012. Available from: URL: http://​dx.​doi.​org/​10.​1097/​IJG.​0b013e31820d7d19​ - USA
Metadaten
Titel
Bevacizumab/ranibizumab
Ocular hypertension following intravitreal administration: 23 case reports
Publikationsdatum
01.08.2012
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2012
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.2165/00128415-201214140-00043

Weitere Artikel der Ausgabe 1/2012

Reactions Weekly 1/2012 Zur Ausgabe

Case report

Antibacterials

Case report

Cefditoren

Case report

Verteporfin